Semaglutide Phase 2 Trial on Aging and Healthspan Not Yet Recruiting

A new trial update for semaglutide was recorded on November 6, 2026. The study, titled "Validation & Intervention Testing for Aging, Longevity and Healthspan," is registered as NCT07923630. It is listed as a Phase 2 trial. Its current status is not yet recruiting, meaning enrollment has not started as of this update. No results or outcome data have been posted for this trial at this stage. The registration provides only the trial title, phase, and recruitment status as of the update date. Semaglutide remains an approved compound, and this listing reflects a new clinical trial record rather than a change in its approved uses. Further details, including eligibility criteria and expected enrollment timelines, may be added to the registry as the trial progresses toward recruitment. Readers interested in tracking this study can refer to the official registry entry for updates. For additional background on semaglutide, including its approved status and general profile, see the compound overview linked with this brief.